Premium
Reducing irinotecan‐associated diarrhea in children
Author(s) -
Wagner Lars M.,
Crews Kristine R.,
Stewart Clinton F.,
RodriguezGalindo Carlos,
McNallKnapp Rene Y.,
Albritton Karen,
Pappo Alberto S.,
Furman Wayne L.
Publication year - 2008
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.21280
Subject(s) - irinotecan , medicine , diarrhea , intensive care medicine , blood cancer , pediatric cancer , clinical trial , oncology , cancer , colorectal cancer
Irinotecan is increasingly being used in pediatric oncology. Amelioration of diarrhea associated with protracted irinotecan administration may reduce morbidity and improve dose intensity. In this review, we discuss what is known about the pathogenesis of this toxicity as well as potential predisposing genetic factors. We comprehensively summarize the literature regarding available prevention and treatment strategies, and report data on the use of cephalosporin prophylaxis in 51 patients treated on various pediatric trials. This approach is feasible in children and allows for tolerance of higher doses of protracted irinotecan. Pediatr Blood Cancer 2008; 50:201–207. © 2007 Wiley‐Liss, Inc.